About Us.

We launch disruptive biotech ventures with a focus on those developing disease-modifying genetic and cellular medicines. Genetic and anatomical repair of tissues is a commercially proven approach for treatment of life-threatening conditions. Correcting an underlying deficit within a cell or tissue can halt degeneration and reverse the course of disease.

Highlighted Venture Deal: Kenai Therapeutics

$82 Million Series A
Financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group, with participation from Euclidean Capital and Saisei Ventures

Highlighted Pharma Deal: Opsis Therapeutics

$70+ Million Strategic R&D Alliance
Bayer subsidiary BlueRock Therapeutics optioned three programs for an up-front, undisclosed milestone payments, and up to low-double digit tiered royalty

Launched Companies.

Papillon Therapeutics is a clinical stage biotechnology company advancing multi-systemic genetic medicines for diseases with neurologic, cardiac, and other tissue pathologies. The company’s clinical stage program reported positive data in a Phase 1/2 clinical trial and is being advanced by Novartis. Following that program are three preclinical programs targeting Friedreich's ataxia, Danon disease, and Alzheimer’s disease.

StemCardia is developing therapies engineered to repair and strengthen the heart. No curative treatments are available for chronic heart disease, the leading cause of death. The heart does not regenerate itself, inspiring our approach to restore cardiac muscle cells. The company’s lead program is an engineered pluripotent stem cell (PSC)-derived cardiac muscle cell with the potential to re-muscularize and restore contractile function to the chronically failing heart.

Kenai Therapeutics is a biotechnology company pioneering next generation approaches to cure neurological disorders. The Company utilizes allogeneic induced pluripotent stem cell (iPSC) technology, a Nobel Prize-winning breakthrough that enables scientists to manufacture many human cell types, in order to advance Kenai’s off-the-shelf neuron replacement therapeutics. By focusing on an iPSC technology platform, and forging partnerships with global leaders in surgical delivery and clinical development, Kenai is dedicated to advancing a best-in-class pipeline targeting neurological diseases.

Opsis Therapeutics is a company focused on advancing a pipeline of cell replacement therapies targeting ocular diseases. Leveraging innovations in induced pluripotent cell (iPSC) generation, retinal cell differentiation, and functional biomaterials, Opsis Therapeutics is developing cell therapies for patients with dry age-related macular degeneration (AMD), inherited macular degenerations (IMDs) and inherited retinal diseases (IRDs).

Vascugen is dedicated to revolutionizing the standard of care for millions of patients suffering from severe conditions caused by restricted blood flow to tissues. Particularly for diabetic patients at high risk for limb amputation and associated morbidity. The company’s lead program is an induced-pluripotent stem cell (iPSC)-derived vasculogenic cell with the potential to forge new blood vessels in oxygen-starved tissues.

RPRD® (Right Patient Right Drug®) Diagnostics specializes in providing innovative precision medicine solutions, including diagnostic, analysis, and support services to clinicians, researchers, and drug developers. With decades of combined experience, RPRD’s team of experts specialize in both comprehensive pharmacogenomics (PGx) and tailored panels using several cutting-edge technologies.

Dianomi Therapeutics was a development stage biopharmaceutical company advancing a pipeline of next generation treatments for inflammatory diseases, initially targeting osteoarthritis. The company’s proprietary Mineral Coated Microparticle (MCM) technology enables formulation of proven drugs for improved delivery, stability, and function.